BioSpace News Archive

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 4,800 shares of the Company’s common stock at an exercise price per share of $16.18, which was the closing price on October 23, 2023, and restricted stock units to acquire a total of 2,400 shares of the Company’s common stock.

Owens & Minor, Inc. plans to release financial results for the third quarter of 2023 on Friday, November 3, 2023, before trading begins on the New York Stock Exchange.

Servier today announced the U.S. Food and Drug Administration (FDA) has approved TIBSOVO® (ivosidenib tablets) for the treatment of patients with isocitrate dehydrogenase 1 (IDH1)-mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS).

PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) announces the approval of its phase 1 study clinical design in endocarditis infections caused by Staphylococcus aureus (S. aureus) by the French National Agency for the Safety of Medicines and Health Products (ANSM) and the South-East II-Lyon Ethics Committee (Comité de Protection des Personnes - CPP).

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced it will report financial results for the third quarter ended September 30, 2023, after the market close on Tuesday, November 7, 2023.

Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, announced the appointment of Saul Fink, Ph.D., as Chief Technology Officer.

Alphatec Holdings, Inc., a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced that it has commenced a proposed underwritten public offering of $150 million of shares of its common stock.

Globus Medical, Inc., a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September 30, 2023 after the market close on Tuesday, November 7, 2023.

STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 second quarter financial results at 9:00 a.m. ET on November 8, 2023.

Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2023.